- Home
- Collections
- Congress on Demand 2021: Feline Medicine and Surgery
Congress on Demand 2021: Feline Medicine and Surgery
We are pleased to present a selection of live and on-demand lectures from BSAVA virtual Congress 2021 that cover feline medicine and surgery. This collection can be purchased as a standalone item, with a discount for BSAVA members. Visit our Congress on Demand information page for information about how to access the rest of our 2021 congress lectures.
Collection Contents
3 results
-
-
Feline IMHA
BSAVA Congress Proceedings 2021Author Nikki ReedImmune-mediated haemolytic anaemia occurs less commonly in cats than dogs. Young to middle-aged cats appear most commonly affected. In addition, it may be more difficult to diagnose for several reasons: jaundice is less commonly seen on clinical examination; spherocytosis is not reliable in cats, as their normal red blood cells are smaller and lack central pallor; cats are more prone to haemolysis from oxidative damage due to e.g. drugs or toxins (methimazole, paracetamol, garlic, onions), Heinz Body anaemia (diabetes mellitus) enzymopathies (pyruvate kinase deficiency); cat erythrocytes commonly form rouleaux, which can be misinterpreted as agglutination; IMHA may be non-regenerative, decreasing the index of suspicion of IMHA as the cause of anaemia. As with canine disease, primary IMHA must be differentiated from secondary IMHA. Recognised causes of secondary IMHA include infections (e.g. M. haemofelis, Feline Coronavirus, retrovirus infection, Babesia), inflammatory disease processes (e.g. pancreatitis, cholangiohepatitis) and drugs (e.g. propylthiouracil). There is no evidence that vaccination can act as a trigger for IMHA in cats, and the evidence for neoplasia acting as a trigger appears weak. Prednisolone forms the mainstay of therapy, with additional immunosuppressive drugs such as ciclosporin, chlorambucil and mycophenolate mofetil also having been used in conjunction with prednisolone.
-
-
-
Feline chronic gingivitis and stomatitis: an update
BSAVA Congress Proceedings 2021Author Boaz ArtiFeline chronic gingivitis stomatitis part 1 – what it is and managing expectations: Feline chronic gingivostomatitis (FCGS) is a painful oral mucosal inflammatory disease presented in cats. The observable characteristics of FCGS is ulcerative and/or proliferative mucosal inflammation in the area lateral to the palatoglossal folds with or without gingival inflammation. The cause of feline gingivostomatitis is currently elusive, but it can be inferred that a chronic antigenic stimulation, such as a viral infection, results in an inappropriate immune response. Full-mouth tooth extraction is the current standard of care to treat FCGS. About 70% of affected cats will have significant improvement with this dental procedure, but approximately 30% of cats will not respond and will have a poor quality of remaining life. Non-responding cats will need lifelong medical management and severely affected cats will often be euthanized. Therefore, managing client expectations is a very important aspect of managing the disease. This lecture covers current evidence-based knowledge on FCGS as well as therapeutic approaches.
Feline chronic gingivitis stomatitis part 2 – stem cell therapy: FCGS is an immune mediated oral mucosal disease. In that context, cats affected by FCGS demonstrate systemic elevation of cytotoxic T cells (CD8 cells) and other abnormalities indicating an aberrant immune system. Mesenchymal stem cells (MSC) are multipotent stem cells. MSC reside in most organs and tissues such as bone marrow, adipose, and periodontal ligament. Furthermore, MSC has a profound regenerative ability attributed in part to their ability modulate both innate and adaptive immunity. Hence, a therapeutic approach was designed whereby mesenchymal stem cells (MSCs) capable of immunomodulation and significant regenerative capacity were administered systemically to cats that did not respond to extraction therapy. MSCs immune modulatory properties include decreased T-cell and B cell proliferation and function and altered lymphocytes phenotypes. The efficacy of MSCs for the treatment of non-responsive FCGS has been an ongoing study, for the past 9 years, tested in several clinical trials. In these clinical trials, approximately 60-70% of cats had a positive response rate. This lecture discusses the general concept of MSC immunomodulation therapy as well as the clinical outcome of MSC therapy for cats with FCGS and future directions.
-
-
-
Feline chronic gingivostomatitis: recent updates and future perspectives
BSAVA Congress Proceedings 2021Author Boaz ArtiFeline chronic gingivostomatitis (FCGS), a severe inflammatory oral disease of cats, is characterised by immune-mediated oral inflammation affecting the caudal oral mucosa as well as the gingival mucosa. In the past 10 years, several key studies paved the road towards better understanding of the etiopathogenesis of FCGS and improving treatment options. This lecture focuses on recent discoveries and current understandings in both etiopathogenesis and therapeutic options including stem cell therapy and immune modulation. Moreover, with the emerging field of regenerative medicine, this lecture informs practitioners on the practicability of stem cell therapy for FCGS. Finally, a path from current discoveries towards clinical applications is discussed.
-